MedTrace Logo

Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

NCT00954122 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2013-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.

Conditions

Interventions

DRUG

Quetiapine XR (Seroquel XR)

Tablet, oral, once daily

Sponsors & Collaborators

Principal Investigators

  • Ahmad Hatim Sulaiman,, M Psyc · University of Malaya

  • Badiah Yahya, MD · Hospital Permai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00954122 on ClinicalTrials.gov